Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model

Abstract

Aim

Despite new therapies, castration-resistant prostate cancer (CRPC) is still incurable. Intercellular Adhesion Molecule 1 (ICAM-1) is a well-characterized cell surface protein involved in prostate cancer pathogenesis, differentially expressed during transition from hormone-sensitive to CRPC. This study aimed to investigate ICAM-1 as a target for imaging and radioimmunotherapy of CRPC.

Methods

Anti-ICAM-1 antibody R6.5 was labeled with ¹¹¹In or ¹⁷⁷Lu, and a non-specific antibody with ¹⁷⁷Lu. In vitro uptake of R6.5 was tested in PC-3 prostate cancer cells. Biodistribution studies, SPECT/CT imaging, and autoradiography were performed in a PC-3 xenograft model.

Results

In vitro uptake of R6.5 ([¹⁷⁷Lu]Lu-R6.5) increased during 6 h of incubation. The uptake was higher at lower mAb concentration and could be blocked by 500 nM of unlabeled R6.5. In vivo and ex vivo biodistribution showed that [¹¹¹In]In-R6.5 and [¹⁷⁷Lu]Lu-R6.5 targeted the xenograft tumors better than the control Ab, however [¹¹¹In]In-R6.5 had better tumor uptake than [¹⁷⁷Lu]Lu-R6.5, probably due to less aggressive conjugation with chelator and smaller tumor sizes. From 24 h post-injection, the tumors in mice injected with [¹¹¹In]In-R6.5 and [¹⁷⁷Lu]Lu-R6.5 were visible on SPECT, optimal contrast at 48 h. Uptake was low in normal organs except the spleen and liver for all mAbs. Autoradiography showed [¹¹¹In]In-R6.5 and [¹⁷⁷Lu]Lu-R6.5 accumulated along the edges of viable tumor. The control Ab tended to accumulate in partly necrotic areas.

Conclusion

This study demonstrates ICAM-1 as a potential target for theragnostics in CRPC.

Keywords

ICAM-1 - CD54 - R6.5 - prostate cancer - radionuclide therapy

Publication History

Received: 27 May 2024

Accepted after revision: 19 February 2025

Article published online:
18 March 2025

• References

• 1 Min IM, Shevlin E, Vedvyas Y. et al. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors. Clin Cancer Res 2017; 23: 7569-7583
• 2 Sumanasuriya S, De Bono J. Treatment of Advanced Prostate Cancer – A Review of Current Therapies and Future Promise. Cold Spring Harb Perspect Med 2018; 8
• 3 Zhao H, Kim Y, Wang P. et al. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 2005; 63: 187-197
• 4 Conrad F, Zhu X, Zhang X. et al. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl) 2009; 87: 507-514
• 5 Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. International journal of clinical and experimental pathology 2009; 2: 553
• 6 Reina M, Espel E. Role of LFA-1 and ICAM-1 in Cancer. Cancers 2017; 9: 153
• 7 Chen PC, Lin TH, Cheng HC. et al. CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis 2012; 33: 937-945
• 8 Li C, Liu S, Yan R. et al. CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. Theranostics 2017; 7: 67-80
• 9 Jeong JU, Uong TNT, Chung WK. et al. Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells. Cytotherapy 2018; 20: 715-727
• 10 Sipkins DA, Gijbels K, Tropper FD. et al. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. Journal of neuroimmunology 2000; 104: 1-9
• 11 Weller GE, Villanueva FS, Tom EM. et al. Targeted ultrasound contrast agents: In vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnology and bioengineering 2005; 92: 780-788
• 12 Mosley M, Torres JB, Allen D. et al. Immuno-imaging of ICAM-1 in tumours by SPECT. Nuclear Medicine and Biology 2020; 84: 73-79
• 13 Li M, Wei W, Barnhart TE. et al. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. European journal of nuclear medicine and molecular imaging 2021; 48: 2737-2748
• 14 Qian WJ, Yan JS, Gang XY. et al. Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation. Bba-Rev Cancer 2024; 1879
• 15 Cosimi AB, Conti D, Delmonico FL. et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4604-4612
• 16 Furuya K, Takeda H, Azhar S. et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001; 32: 2665-2674
• 17 EAST Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57: 1428-1434
• 18 Salmela K, Wramner L, Ekberg H. et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999; 67: 729-736
• 19 Schneider D, Berrouschot J, Brandt T. et al. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol 1998; 40: 78-83
• 20 Vuorte J, Lindsberg PJ, Kaste M. et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol 1999; 162: 2353-2357
• 21 Örbom A, Ahlstedt J, Serén T. et al. Characterization of a double-sided silicon strip detector autoradiography system. Medical Physics 2015; 42: 575-584
• 22 Yoshida K, van den Berg TK, Dijkstra CD. Two functionally different follicular dendritic cells in secondary lymphoid follicles of mouse spleen, as revealed by CR1/2 and FcR gamma II-mediated immune-complex trapping. Immunology 1993; 80: 34-39
• 23 Vilhelmsson Timmermand O, Örbom A, Altai M. et al. A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen. Cancers 2021; 13: 3469
• 24 Altai M, Strand J, Rosik D. et al. Influence of Nuclides and Chelators on Imaging Using Affibody Molecules: Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with ⁶⁸Ga and ¹¹¹In via Maleimido Derivatives of DOTA and NODAGA. Bioconjugate Chemistry 2013; 24: 1102-1109
• 25 Williams LE, Duda RB, Proffitt RT. et al. Tumor Uptake as a Function of Tumor Mass – a Mathematic Model. Journal of Nuclear Medicine 1988; 29: 103-109
• 26 Jang SH, Wientjes MG, Lu D. et al. Drug delivery and transport to solid tumors. Pharm Res 2003; 20: 1337-1350
• 27 Heneweer C, Holland JP, Divilov V. et al. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med 2011; 52: 625-633
• 28 Fujimori K, Covell DG, Fletcher JE. et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31: 1191-1198
• 29 Ruggiero A, Holland JP, Hudolin T. et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 2011; 52: 1608-1615
• 30 Smith-Jones PM, Vallabhajosula S, Navarro V. et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44: 610-617
• 31 Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-592
• 32 Lammers T, Kiessling F, Hennink WE. et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012; 161: 175-187
• 33 Choi IK, Strauss R, Richter M. et al. Strategies to increase drug penetration in solid tumors. Front Oncol 2013; 3: 193
• 34 Örbom A, Eriksson SE, Elgstrom E. et al. The Intratumoral Distribution of Radiolabeled ¹⁷⁷Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model. J Nucl Med 2013; 54: 1404-1410
• 35 Timmermand OV, Elgqvist J, Beattie KA. et al. Preclinical efficacy of hK2 targeted [Lu-177]hu11B6 for prostate cancer theranostics. Theranostics 2019; 9: 2129-2142
• 36 Morelock MM, Rothlein R, Bright SM. et al. Isotype choice for chimeric antibodies affects binding properties. J Biol Chem 1994; 269: 13048-13055
• 37 Mileski WJ, Burkhart D, Hunt JL. et al. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. J Trauma 2003; 54: 950-958
• 38 Cilliers C, Guo H, Liao J. et al. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. The AAPS journal 2016; 18: 1117-1130
• 39 Rhoden JJ, Wittrup KD. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci 2012; 101: 860-867